... = 14; deferiprone, n = 11, and deferasirox, n = 15) or in certain combinations (deferoxamine plus deferasirox, n = 2, and deferiprone plus deferoxamine, n = 18). Ferritin serum levels were not equally distributed among patients subjected to the different chelation schedules (p = 0.02). Patients...

... deferiprone (DFP) combined with 40 mg/kg/dose s.c. desferrioxamine (DFO) twice weekly were given to transfusion-dependent β-thalassemia children. Results: Enrolled patients (9 with β-thalassemia major and 33 with β-thalassemia hemoglobin E), ranging from 3 to 18 years in age, were divided into 3 groups; group...

...R. Galanello; S. Campus Iron overload is one of the major causes of morbidity in patients with thalassemia major. Deferiprone (DFP), an orally active iron chelator, emerged from an extensive search for new drugs to treat iron overload. Comparative studies have shown that at comparable doses...

... or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Iron chelators Iron chelation Desferrioxamine B Deferiprone Malaria Cerebral malaria Plasmodium falciparum Plasmodium vivax Cellular immunity Lipid peroxidation '^ to k g...

...Nancy F. Olivieri Data from several trials have provided direct and supportive evidence for the efficacy of deferiprone in the treatment of iron overload in thalassemia major. Deferiprone has been shown to induce sustained decreases in body iron to concentrations associated with survival free from...

...A. Taher; E. Aoun; A.I. Sharara; F. Mourad; W. Gharzuddine; S. Koussa; A. Inati; A.P. Dhillon; A.V. Hoffbrand Twelve thalassaemia major patients have been given deferiprone 75 mg/kg body weight daily as iron chelation therapy for 5 years. Their ages ranged from 18 to 34 years (mean 24.2) at the end...

...Giovanni Carlo Del Vecchio; Elisabetta Crollo; Federico Schettini; Francesco Schettini; Roland Fischer; Domenico De Mattia The effectiveness of deferiprone (L1) and the influence of other factors were determined in a clinical setting. Patients of Southern Italian origin, affected by β-thalassaemia...

...Y. Aydinok; G. Nisli; K. Kavakli; C. Coker; M. Kantar; N. Çetingül The effectiveness of the sequential use of deferiprone and desferrioxamine (DFO) in children with thalassaemia major was examined. Seven thalassaemic children in whom urinary iron induced by deferiprone was sufficient to maintain...

...A. Taher; F.M. Chamoun; S. Koussa; M. Abi Saad; A.I. Khoriaty; R. Neeman; F.H. Mourad We report our experience with deferiprone (L1) (DFP) in 17 thalassemic patients, followed up in one center in Lebanon, who were initially on desferrioxamine and then shifted to DFP at a dose of 50–75 mg/kg/day...